A Partially Randomized, Partly Placebo Controlled Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA-BN RSV Vaccine After Intranasal and Intramuscular Administration

Trial Profile

A Partially Randomized, Partly Placebo Controlled Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA-BN RSV Vaccine After Intranasal and Intramuscular Administration

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs MVA-BN RSV (Primary) ; MVA-BN RSV (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Jul 2017 Planned End Date changed from 1 Jul 2017 to 1 Aug 2019.
    • 20 Jul 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Aug 2019.
    • 20 Jul 2017 Planned initiation date changed from 1 Sep 2016 to 1 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top